Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.

[1]  P. Lam,et al.  Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. , 2005, Journal of medicinal chemistry.

[2]  L. Drouet,et al.  Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events , 2005, European journal of clinical investigation.

[3]  Deepak L. Bhatt,et al.  Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality , 2005, Journal of thrombosis and haemostasis : JTH.

[4]  V. Fuster,et al.  Clinical and Experimental Experience with Factor Xa Inhibitors , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[5]  K. Mann,et al.  The dynamics of thrombin formation. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[6]  R. Knabb,et al.  Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent. , 2006, Cardiovascular drug reviews.

[7]  P. Lam,et al.  Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits , 2002, Journal of Pharmacology and Experimental Therapeutics.

[8]  R. Leadley.  Coagulation factor Xa inhibition: biological background and rationale. , 2001, Current topics in medicinal chemistry.

[9]  P. Lam,et al.  Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. , 2001, Journal of medicinal chemistry.

[10]  R. Knabb,et al.  Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  J. Stürzebecher,et al.  Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. , 1999, Thrombosis research.

[12]  G M Pacifici,et al.  Methods of Determining Plasma and Tissue Binding of Drugs , 1992, Clinical pharmacokinetics.

[13]  H. Staudinger,et al.  Über neue organische Phosphorverbindungen III. Phosphinmethylenderivate und Phosphinimine , 1919 .